# US 5,332,759 A · Naphthalene amides and sulphonamides, processes for their preparation and pharmaceutical compositions containing them > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,332,759 A - Document ID: US5332759A - Status: Granted - Kind: A - Application number: 08/009,922 - Filed: 1993-01-21 - Granted: 1994-07-26 - Earliest claimed: 1992-01-22 - Assignees: Adir et Compagnie - Inventors: Patrick Depreux; Daniel Lesieur; Habib Abdellaoui; Beatrice Guardiola; Gerard Adam; Pierre Renard; Bruno Pfeiffer - Web page: https://patentgrep.com/patent/US5332759A ## CPC - C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 25/04: Centrally acting analgesics, e.g. opioids - A61P 25/06: Antimigraine agents - C07C 311/35: of an unsaturated carbon skeleton containing rings - C07D 209/52: condensed with a ring other than six-membered - C07D 295/26: Sulfur atoms - C07C 2601/14: The ring being saturated - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS ## Abstract The invention relates to compounds of the general formula (I): ##STR1## wherein R.sub.3 represents a group ##STR2## R.sub.1, R.sub.2, R.sub.6, R.sub.7 being as defined in the description. Medicinal product useful in treating a disorder due to vasodilatation of the vascular system. ## Claims ### Claim 1 A compound selected from those of the formula (I): ##STR61## it being possible for each of the two substituents, independently of the other, to be located on either one of the two naphthalene rings, and wherein R.sub.1 and R.sub.2, which are the same different, each represents, independently of the other, a radical selected from: hydrogen, straight-chain or branched alkyl having 1 to 6 carbon atoms, inclusive, cycloalkyl, having 3 to 7 carbon atoms, inclusive, or cycloalkyl(C1-C4)alkyl, straight-chain or branched alkyl having 2 to 6 carbon atoms inclusive, optionally substituted aryl, and optionally substituted aralkyl of which the alkyl chain has 1 to 3 carbon atoms, inclusive, R.sub.3 represents: ##STR62## wherein R.sub.6 and R.sub.7, which are the same or different, have the same definition as R.sub.1 and R.sub.2, an optical isomer therefore, and an addition salt with a pharmaceutically-acceptable mineral or organic acid; "aryl" meaning a group selected from phenyl, naphthyl; the expression "optionally substituted meaning that the aromatic nucleus or nuclei may be substituted by one or more radicals selected from hydroxy, halogen, trifluoromethyl, nitro, straight-chain or branched alkyl having 1 to 6 carbon atoms, inclusive, and straight-chain or branched alkoxy having 1 to 6 carbon atoms, inclusive. ### Claim 2 (depends on 1) A compound according to claim 1 selected from those of the formula (I.sub.A): ##STR63## wherein, it being possible for each of the two substituents, independently of the other, to be located on either one of the two naphthalene rings, R.sub.1, R.sub.2, R.sub.6 and R.sub.7 are as defined in claim 1, an optical isomer thereof, and an addition salt with a pharmaceutically-acceptable mineral or organic acid. ### Claim 3 (depends on 1) A compound according to claim 1 in which the two substituents are located at apices 1 and 7 of the naphthalene nucleus and which corresponds to a compound selected from those of the following formula: ##STR64## wherein R.sub.1, R.sub.2, R.sub.3 are as defined in claim 1, an optical isomer thereof, and an addition salt with a pharmaceutically-acceptable mineral or organic acid. ### Claim 4 (depends on 1) A compound according to claim 1 in which the two substituents are located at apices 1 and 7 of the naphthalene nucleus and which corresponds to a compound selected from those of the following formula: ##STR65## wherein R.sub.1, R.sub.2, R.sub.3 are as defined in claim 1, an optical isomer thereof, and an addition salt with a pharmaceutically-acceptable mineral or organic acid. ### Claim 5 (depends on 1) A compound according to claim 1, which is selected from 2-{1-[2-(dimethylamino)ethyl]naphth-7-yl}-N-methyl-methanesulphonamide of which the formula is shown below, and an addition salt thereof with a pharmaceutically-acceptable mineral or organic acid, ##STR66## ### Claim 6 (depends on 1) A compound according to claim 1, which is selected from 2-{7-[2-(dimethylamino)ethyl]naphth-1-yl}-N-methyl-methanesulphonamide of which the formula is shown below, and an addition salt thereof with a pharmaceutically-acceptable mineral or organic acid, ##STR67## ### Claim 7 (depends on 1) A compound according to claim 1, which is selected from 2-{1-[2-(N-methyl-N-ethylamino)ethyl]naphth-7-yl}-N-methyl-methanesulphona mide of which the formula is shown below, and an addition salt thereof with a pharmaceutically-acceptable mineral or organic acid, ##STR68## ### Claim 8 (depends on 1) A compound according to claim 1, which is selected from 2-{1-[2-(dimethylamino)ethyl]naphth-7-yl}-N-methyl-methanesulphonamide of which the formula is shown below, and an addition salt thereof with a pharmaceutically-acceptable mineral or organic acid, ##STR69## ### Claim 9 (depends on 1) A compound according to claim 1, which is selected from 2-{1-[2-(N-methylamino)ethyl]naphth-7-yl}-N-methyl-methanesulphonamide of which the formula is shown below, and an addition salt thereof with a pharmaceutically-acceptable mineral or organic acid, ##STR70## ### Claim 10 (depends on 1) A pharmaceutical composition useful in treating a disorder due to vasodilatation of the vascular system, comprising as active principle an effective amount of a compound as claimed in claim 1, in combination with a pharmaceutically-acceptable carrier or diluent. ### Claim 11 (depends on 1) A method of treating a living mammal afflicted with a disorder due to vasodilatation of the vascular system, comprising the step of administering to the said living mammal an amount of a compound as claimed in claim 1, which is effective for alleviation of said disorder.